B

Biohit Oyj
OMXH:BIOBV

Watchlist Manager
Biohit Oyj
OMXH:BIOBV
Watchlist
Price: 2.33 EUR -0.43%
Market Cap: 35.2m EUR
Have any thoughts about
Biohit Oyj?
Write Note

Biohit Oyj
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biohit Oyj
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
Biohit Oyj
OMXH:BIOBV
Cash & Cash Equivalents
€1.8m
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
20%
R
Revenio Group Oyj
OMXH:REG1V
Cash & Cash Equivalents
€13.5m
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
19%
M
Modulight Oyj
OMXH:MODU
Cash & Cash Equivalents
€409k
CAGR 3-Years
-39%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Cash & Cash Equivalents
€6.9m
CAGR 3-Years
45%
CAGR 5-Years
41%
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Cash & Cash Equivalents
€7.1m
CAGR 3-Years
-12%
CAGR 5-Years
29%
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Cash & Cash Equivalents
€3m
CAGR 3-Years
-23%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Biohit Oyj
Glance View

Market Cap
35.4m EUR
Industry
Health Care

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

BIOBV Intrinsic Value
3.37 EUR
Undervaluation 31%
Intrinsic Value
Price
B

See Also

What is Biohit Oyj's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.8m EUR

Based on the financial report for Jun 30, 2024, Biohit Oyj's Cash & Cash Equivalents amounts to 1.8m EUR.

What is Biohit Oyj's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
20%

Over the last year, the Cash & Cash Equivalents growth was 6%. The average annual Cash & Cash Equivalents growth rates for Biohit Oyj have been 22% over the past three years , 7% over the past five years , and 20% over the past ten years .

Back to Top